514 completed, 171 terminated, 157 recruiting, 103 active not recruiting. 1087 Phase 1, 375 Phase 2.
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2027-01-31 | 2026-09-29 |
| Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder Carcinoma BCG Solution, Best Practice, Cystoscopy - Non-Muscle Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 49 | 2027-01-15 | 2026-10-14 |
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-10-01 |
| Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) ATO-101™ - Bladder Cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 24 | 2027-01-01 | 2026-06-08 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer TTP-ICG NIR fluorescent diagnostic agent - NMIBC | Phase 1 / Phase 2 | Not yet recruiting | Yunnan Cancer Hospital | 30 | 2026-10-30 | 2026-09-24 |
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial Calcium electroporation, Intratumoral calcium injection, Transurethral electroporation - Bladder Tumors, Bladder Tumor | Phase 1 | Recruiting | Juan Luis Vásquez | 20 | 2026-10-12 | 2026-10-27 |
| A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC UGN-501 - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 1 | Recruiting | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | 30 | 2026-09-28 | 2026-10-13 |
| Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma casdatifan - Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 12 | 2026-09-21 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure Intravesical Instillation of Disitamab Vedotin Combined with Toripalimab - Bladder Cancer | Phase 1 | Not yet recruiting | Xiangya Hospital of Central South University | 20 | 2026-09-01 | 2026-08-25 |
| Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma Personalized Neoantigen Polyepitope Peptide Vaccine - Renal Cell Carcinoma, Advanced | Phase 1 | Not yet recruiting | Jian Lin | 8 | 2026-09-01 | 2026-07-07 |
| Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM 68Ga-NYM096 injection - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Norroy Bioscience Co., LTD | 20 | 2026-09-01 | 2026-08-17 |
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Canadian Cancer Trials Group | 30 | 2026-08-30 | 2026-10-16 |
| Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01) Cyclophosphamid, Fludarabine, Interleukin 2 subcutaneous injection - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 15 | 2026-08-23 | 2026-10-14 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
Showing 20 of 1087. Sign in to see all of them.
Carcinoma, Renal Cell (609) · Urinary Bladder Neoplasms (360) · Carcinoma, Non-Small-Cell Lung (272) · Melanoma (235) · Kidney Neoplasms (228) · Ovarian Neoplasms (173) · Colorectal Neoplasms (168) · Breast Neoplasms (160) · Neoplasms (148) · Stomach Neoplasms (135) · Neoplasm Metastasis (129) · Squamous Cell Carcinoma of Head and Neck (121) · Pancreatic Neoplasms (118) · Carcinoma, Transitional Cell (117) · Lung Neoplasms (117)
Female Urogenital Diseases (1087) · Female Urogenital Diseases and Pregnancy Complications (1087) · Male Urogenital Diseases (1087) · Urogenital Diseases (1087) · Neoplasms by Site (1082) · Urologic Diseases (1078) · Urogenital Neoplasms (1077) · Neoplasms (939) · Neoplasms by Histologic Type (895) · Neoplasms, Glandular and Epithelial (844) · Carcinoma (784) · Kidney Diseases (751) · Adenocarcinoma (638) · Kidney Neoplasms (531)
pembrolizumab (125) · Nivolumab (82) · Gemcitabine (46) · Cyclophosphamide (42) · Cisplatin (33) · Ipilimumab (33) · Sunitinib (30) · Bevacizumab (29) · Everolimus (28) · Paclitaxel (27) · fludarabine (27) · Docetaxel (25) · atezolizumab (25) · Carboplatin (23) · Magnetic Resonance Spectroscopy (22)
National Cancer Institute (NCI) (79) · Memorial Sloan Kettering Cancer Center (28) · M.D. Anderson Cancer Center (26) · Pfizer (22) · Novartis Pharmaceuticals (18) · Merck Sharp & Dohme LLC (16) · Bristol-Myers Squibb (13) · Eli Lilly and Company (12) · Jonsson Comprehensive Cancer Center (12) · Celldex Therapeutics (11) · GlaxoSmithKline (11) · City of Hope Medical Center (10) · AstraZeneca (9) · Ludwig Institute for Cancer Research (9) · Baylor College of Medicine (8)
United States (803) · Spain (104) · China (95) · Canada (89) · Australia (86) · France (86) · United Kingdom (85) · South Korea (60) · Italy (57) · Germany (48) · Netherlands (41) · Japan (40) · Belgium (39) · Israel (28) · Taiwan (25)
Steven A Rosenberg, M.D. (5) · Dean F. Bajorin, MD (4) · Sumanta K Pal (4) · Aung Naing, MD (3)
PMID 31401903, PMID 32499241, PMID 39462179, PMID 19949018, PMID 22002018, PMID 30807645, PMID 37093350, PMID 37496366, PMID 40712111, PMID 41044356, PMID 11410496, PMID 12727829, PMID 15126782, PMID 15814645, PMID 15875784, PMID 15928663, PMID 16234526, PMID 16914576, PMID 17340590, PMID 17395103, PMID 17409436, PMID 17452976, PMID 17893567, PMID 18245546, PMID 18272024, PMID 18281544, PMID 18391430, PMID 18470481, PMID 18833002, PMID 19075272, PMID 19100600, PMID 19179301, PMID 19192962, PMID 19430790, PMID 19636012, PMID 19706807, PMID 19755389, PMID 20044751, PMID 20068553, PMID 20142724, PMID 20145168, PMID 20179219, PMID 20305636, PMID 20407240, PMID 20460632, PMID 20797845, PMID 21277078, PMID 21403127, PMID 21447719, PMID 21633906
2023 (21), 2019 (13), 2016 (11), 2025 (9), 2017 (8), P30CA033572 (8), 2015 (7), 2018 (7), 2014 (6), P30CA015704 (5), 2009 (4), P30CA072720 (4), U01CA070095 (4), U01CA132123 (4), UM1CA186644 (4)